Dr Smith and colleagues have provided a valuable update to recommendationsregarding the use of vaccinia immune globulin (VIG) in the treatment of ocularcomplications of smallpox immunization that were not included in my recentsuccinct review.1 This update includes theimportant personal communication to the authors from Dr Pavan-Langston thatshe has withdrawn her previous recommendation for the use of topical administrationof VIG as well as the publication by the Centers for Disease Control (CDC)of revised recommendations for the use of intramuscular or intravenous VIGfor ocular vaccinia.
Semba RD. The Ocular Complications of Smallpox andSmallpox Immunization—Reply. Arch Ophthalmol. 2004;122(9):1407-1408. doi:10.1001/archopht.122.9.1407-b